AIM
MRNA icon

AXA Investment Managers’s Moderna MRNA Stock Holding History

AXA Investment Managers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$24.4K Buy
+946
New +$26.4K ﹤0.01% 1162

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AXA Investment Managers's MRNA Position: Q3 2025 in Review

AXA Investment Managers opened a new position in Moderna (MRNA) in Q3 2025: 946 shares worth $24.4K. The stake represents ﹤0.01% of the portfolio and ranks #1162 among its holdings.

643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • AXA Investment Managers held 946 shares of Moderna worth $24.4K as of Q3 2025.
  • Moderna was a new AXA Investment Managers position in Q3 2025.
  • Moderna made up ﹤0.01% of AXA Investment Managers's portfolio in Q3 2025, its #1162 holding.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.